Superstring Capital Management LP
In its 13F for Q4 2024 (holdings as of December 31, 2024, filed February 14, 2025), Superstring Capital Management LP reported 38 stock positions worth $113.9 million. Its top holding was Oric Pharmaceuticals (ORIC) at 11.2% of the portfolio, followed by Terns Pharmaceuticals (TERN, 9.8%) and Zai Lab Ltd.-ADR (ZLAB, 9.3%). Compared with Q3 2024, it opened 19 new positions, sold out of 8, added to 9 and reduced 8. The biggest buy was a new position in Cogent Biosciences (COGT) and the biggest sale Cytokinetics (CYTK, shares −40%).
- Most Recent 13F
- Q2 2026
- Location
- NEW YORK, NY
- CIK
- 0001931118
- Portfolio Value
- $113.9M (Q4 2024)
- SEC Filing
- 0001931118-25-000002 ↗ filed Feb 14, 2025
Holdings Value
Holdings 38 stocks · $113.9M
| ORIC Oric Pharmaceuticals Inc. | 11.20% | 1,580,745 | $12.8M | Add +66.5% |
| TERN Terns Pharmaceuticals Inc. | 9.83% | 2,020,562 | $11.2M | Add +49.8% |
| ZLAB Zai Lab Ltd.-ADR | 9.28% | 403,630 | $10.6M | Reduce -35.6% |
| NVCR Novocure Ltd. | 7.51% | 286,970 | $8.6M | Reduce -26.9% |
| BBIO Bridgebio Pharma Inc. | 6.32% | 262,141 | $7.2M | Add +15.6% |
| COGT Cogent Biosciences Inc. | 6.24% | 910,865 | $7.1M | New |
| CYTK Cytokinetics Inc. | 5.35% | 129,389 | $6.1M | Reduce -40.0% |
| GPCR Structure Therapeutics Inc. | 5.16% | 216,811 | $5.9M | Reduce -4.5% |
| IDYA Ideaya Biosciences Inc. | 5.13% | 227,102 | $5.8M | New |
| URGN Urogen Pharma Ltd. | 2.82% | 301,206 | $3.2M | New |
| SMMT Summit Therapeutics Inc. | 2.58% | 164,564 | $2.9M | New |
| TIL Instil Bio Inc. | 2.48% | 148,017 | $2.8M | Add +37.6% |
| PTGX Protagonist Therapeutics Inc. | 2.34% | 68,892 | $2.7M | New |
| INSM Insmed Inc. | 2.18% | 35,966 | $2.5M | New |
| FATE Fate Therapeutics Inc. | 2.00% | 1,379,556 | $2.3M | Reduce -6.0% |
| LEGN Legend Biotech Corp.-ADR | 1.99% | 69,594 | $2.3M | Add +15.0% |
| TARA Protara Therapeutic Inc. | 1.67% | 360,000 | $1.9M | New |
| CABA Cabaletta Bio Inc. | 1.64% | 822,293 | $1.9M | Add +523.9% |
| DYN Dyne Therapeutics Inc. | 1.51% | 73,150 | $1.7M | New |
| SVRA Savara Inc. | 1.37% | 508,338 | $1.6M | Add +154.2% |
| TNGX Tango Therapeutics Inc. | 1.29% | 474,955 | $1.5M | Reduce -20.7% |
| KURA Kura Oncology Inc. | 1.21% | 157,959 | $1.4M | New |
| INCY Incyte Corp. | 1.09% | 18,009 | $1.2M | New |
| ONC Beone Medicines Ltd.-ADR filed as BEIGENE LTD | 1.03% | 6,365 | $1.2M | New |
| VSTM Verastem Inc. | 0.95% | 209,889 | $1.1M | New |
| ETNB 89BIO Inc. | 0.91% | 132,982 | $1.0M | Reduce -77.7% |
| ZBIO Zenas Biopharma Inc. | 0.80% | 111,605 | $914K | No change |
| CAPR Capricor Therapeutics Inc. | 0.67% | 55,229 | $762K | Reduce -83.6% |
| KYTX Kyverna Therapeutics Inc. | 0.60% | 182,177 | $681K | New |
| RZLT Rezolute Inc. | 0.53% | 123,184 | $604K | New |
| IPSC Century Therapeutics Inc. | 0.41% | 462,963 | $468K | New |
| ZURA Zura Bio Ltd. | 0.41% | 186,943 | $467K | Add +19.4% |
| EYPT Eyepoint Inc. | 0.32% | 49,375 | $368K | New |
| AXSM Axsome Therapeutics Inc. | 0.32% | 4,268 | $361K | New |
| MDGL Madrigal Pharmaceuticals Inc. | 0.31% | 1,129 | $348K | New |
| LXEO Lexeo Therapeutics Inc. | 0.30% | 52,616 | $346K | New |
| CLYM Climb Bio Inc. | 0.16% | 98,160 | $177K | Add +190.2% |
| LSBCF Lakeshore Biopharma Co. Ltd. | 0.09% | 30,792 | $106K | No change |
Options reported separately and not counted above: ORIC calls ($1.6M).
Portfolio Sells Q3 2024 → Q4 2024
| CYTK Cytokinetics Inc. | Reduce -40.0% | 5.35% | −4.84 |
| ZLAB Zai Lab Ltd.-ADR | Reduce -35.6% | 9.28% | −4.25 |
| CAPR Capricor Therapeutics Inc. | Reduce -83.6% | 0.67% | −3.92 |
| GPCR Structure Therapeutics Inc. | Reduce -4.5% | 5.16% | −3.75 |
| ETNB 89BIO Inc. | Reduce -77.7% | 0.91% | −3.03 |
| NKTX Nkarta Inc. | Sold out | 0.00% | −2.99 |
| TNGX Tango Therapeutics Inc. | Reduce -20.7% | 1.29% | −2.84 |
| FATE Fate Therapeutics Inc. | Reduce -6.0% | 2.00% | −2.59 |
| ALLO Allogene Therapeutics Inc. | Sold out | 0.00% | −1.20 |
| SYRE Spyre Therapeutics Inc. | Sold out | 0.00% | −0.98 |
| BMEA Biomea Fusion Inc. | Sold out | 0.00% | −0.75 |
| TRML Tourmaline Bio Inc. | Sold out | 0.00% | −0.67 |
| CRBP Corbus Pharmaceuticals Holdi | Sold out | 0.00% | −0.47 |
| IMVT Immunovant Inc. | Sold out | 0.00% | −0.32 |
| CGEM Cullinan Therapeutics Inc. | Sold out | 0.00% | −0.31 |
| NVCR Novocure Ltd. | Reduce -26.9% | 7.51% | +2.02 |
Portfolio Buys Q3 2024 → Q4 2024
| COGT Cogent Biosciences Inc. | New | 6.24% | +6.24 |
| IDYA Ideaya Biosciences Inc. | New | 5.13% | +5.13 |
| URGN Urogen Pharma Ltd. | New | 2.82% | +2.82 |
| SMMT Summit Therapeutics Inc. | New | 2.58% | +2.58 |
| ORIC Oric Pharmaceuticals Inc. | Add +66.5% | 11.20% | +2.50 |
| PTGX Protagonist Therapeutics Inc. | New | 2.34% | +2.34 |
| INSM Insmed Inc. | New | 2.18% | +2.18 |
| TARA Protara Therapeutic Inc. | New | 1.67% | +1.67 |
| DYN Dyne Therapeutics Inc. | New | 1.51% | +1.51 |
| KURA Kura Oncology Inc. | New | 1.21% | +1.21 |
| BBIO Bridgebio Pharma Inc. | Add +15.6% | 6.32% | +1.16 |
| INCY Incyte Corp. | New | 1.09% | +1.09 |
| CABA Cabaletta Bio Inc. | Add +523.9% | 1.64% | +1.08 |
| ONC Beone Medicines Ltd.-ADR | New | 1.03% | +1.03 |
| VSTM Verastem Inc. | New | 0.95% | +0.95 |
| SVRA Savara Inc. | Add +154.2% | 1.37% | +0.61 |
| KYTX Kyverna Therapeutics Inc. | New | 0.60% | +0.60 |
| RZLT Rezolute Inc. | New | 0.53% | +0.53 |
| IPSC Century Therapeutics Inc. | New | 0.41% | +0.41 |
| EYPT Eyepoint Inc. | New | 0.32% | +0.32 |
| AXSM Axsome Therapeutics Inc. | New | 0.32% | +0.32 |
| MDGL Madrigal Pharmaceuticals Inc. | New | 0.31% | +0.31 |
| LXEO Lexeo Therapeutics Inc. | New | 0.30% | +0.30 |
| CLYM Climb Bio Inc. | Add +190.2% | 0.16% | +0.00 |
| ZURA Zura Bio Ltd. | Add +19.4% | 0.41% | −0.16 |
| TERN Terns Pharmaceuticals Inc. | Add +49.8% | 9.83% | −0.23 |
| LEGN Legend Biotech Corp.-ADR | Add +15.0% | 1.99% | −0.65 |
| TIL Instil Bio Inc. | Add +37.6% | 2.48% | −3.99 |
Options Activity Q3 2024 → Q4 2024
| ZLAB Zai Lab Ltd.-ADR | call | Sold out | 100,000 | $2.4Mbefore exit |
| ORIC Oric Pharmaceuticals Inc. | call | New | 200,000 | $1.6M |
Calls and puts are listed by the shares they cover; their value is not part of the stock holdings above.
All Filings
| Quarter | Positions | 13F Reported Value | Top Holdings |
|---|---|---|---|
| Q2 2026 | 32 | $158.4M | COGT, AXSM, GMAB, CLDX, TRVI |
| Q1 2026 | 35 | $140.0M | SMMT, IMVT, COGT, SVRA, URGN |
| Q4 2025 | 45 | $186.8M | CDTX, TERN, URGN, COGT, DVAX |
| Q3 2025 | 35 | $101.5M | ZLAB, CDTX, TERN, ETNB, IMVT |
| Q2 2025 | 35 | $80.3M | COGT, VRNA, NBIX, TERN, RARE |
| Q1 2025 | 33 | $83.8M | ZLAB, BBIO, VRNA, LEGN, PFE |
| Q4 2024 | 38 | $113.9M | ORIC, TERN, ZLAB, NVCR, BBIO |
| Q3 2024 | 27 | $111.8M | ZLAB, CYTK, TERN, GPCR, ORIC |
| Q2 2024 | 39 | $79.3M | CYTK, LEGN, TERN, BBIO, ETNB |
| Q1 2024 | 37 | $151.2M | CYTK, NKTX, ETNB, BBIO, SVRA |